viewMedexus Pharmaceuticals Inc

Medexus Pharmaceuticals plans million-share buyback to unlock shareholder value

The specialty pharmaceutical company will seek to repurchase approximately 6.8% of outstanding Medexus stock and around 10% of its public float, or a total of 1,005,333 shares

stem cell
The company's flagship product, Treosulfan, is a conditioning agent used before stem cell transplantation.

Medexus Pharmaceuticals (CVE:MDP), a specialty pharmaceutical company, announced Tuesday that it intends to make a normal course issuer bid to repurchase about a million shares of the company.

The bid represents approximately 6.8% of outstanding Medexus stock and around 10% of its public float, or a total of 1,005,333 shares.

READ: Aequus Pharmaceuticals brings in $2.35 million after closing offering

The Montreal-based company is working with Canaccord Genuity Corp on an automatic securities purchase plan to complete the share buyback. Medexus has submitted a notice of its plan to the TSX Venture Exchange for approval.

The Medexus board said in a statement that it believes the market price of the shares may not fully reflect their underlying value, and that the proposed plan is in the best interest of the company and a desirable use of corporate funds.

The company also noted that the repurchase plan is advantageous to remaining Medexus shareholders and will increase the proportionate value of each shareholder.

Shares will be purchased on the open market through the TSX Venture Exchange or by any other means permitted by the exchange. The repurchase price will be the prevailing market price at the time of purchase.

The company anticipates the bid to commence by May 16 and will conclude by May 15, 2020 or once the company has purchased the maximum number of shares outlined in the bid. Medexus may also provide a notice of termination to the exchange at any time.

Commercial platform

Medexus is a specialty pharmaceutical company with a North American commercial platform, focused on auto-immune disease and pediatrics.

It recently received Health Canada authorization to distribute Treosulfan through a special access program.

Treosulfan is a conditioning agent used before stem cell transplantation.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Medexus Pharmaceuticals Inc

Price: 2.8 CAD

Market: TSX-V
Market Cap: $39.36 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...



Medexus expects public reimbursement for its joint-disease drug to roll out...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive that price negotiations for Triamcinolone Hexacetonide Injectable Suspension 20mg/mL (TH) in Canada are complete. d’Entremont says the public reimbursement is expected to roll out in a few of the Canadian...

on 04/09/2020

2 min read